查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2026870

全基因組定序市場預測至2034年－按產品、類型、工作流程、技術、應用、最終用戶和地區分類的全球分析

Whole Genome Sequencing Market Forecasts to 2034 - Global Analysis By Product (Consumables, Instruments and Services), Type (Small Whole Genome Sequencing and Large Whole Genome Sequencing), Workflow, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球全基因組定序市場規模將達到 660 億美元，並在預測期內以 13.5% 的複合年成長率成長，到 2034 年將達到 1820 億美元。

全基因組定序（WGS）是一種用於確定生物體基因組完整DNA序列的綜合技術。基因組是包含所有基因和非編碼區在內的完整DNA序列，它攜帶生物體發育、功能和維持生存所需的遺傳訊息。全基因組定序在基因組學領域的研究開發和臨床應用方面發揮著至關重要的作用。

根據美國疾病管制與預防中心 (CDC) 的統計數據，美國大約每 707 名新生兒中就有 1 名患有唐氏症。

遺傳性疾病盛行率增加

全基因組定序（WGS）是一種強大的工具，可用於識別與多種疾病相關的基因變異。隨著遺傳疾病盛行率的上升，對準確、全面的診斷方法的需求也日益成長。 WGS能夠對個體的整個基因組進行全面分析，從而深入了解疾病的遺傳基礎。這推動了研究人員深入理解潛在的遺傳機制。此外，人們越來越認知到早期檢測和早期療育在遺傳疾病管理中的重要性，這也促進了對WGS的需求。

特定疾病臨床效用的局限性

在某些病理情況下，特別是複雜且多因素疾病中，其遺傳基礎可能並不明確，或難以直接應用於臨床實務。在某些情況下，特定基因組學觀察與臨床結果之間的關聯性可能尚未得到充分證實。這種實用資訊的缺乏限制了全基因組定序（WGS）的臨床效用，因為醫療專業人員可能難以將遺傳數據應用於治療決策。此外，如何應對這些情況也引發了倫理方面的擔憂。因此，WGS在臨床實踐中的應用受到阻礙。

腫瘤學領域應用範圍的擴大

全基因組定序 (WGS) 能夠對患者的基因組成進行全面分析，從而加深對癌症分子機制的理解。這有助於識別促進癌細胞增殖的特定基因突變和改變。 WGS 數據在腫瘤學研究中的應用對於篩選適合臨床試驗的候選患者至關重要。隨著臨床證據的累積以及該技術日益普及和成本降低，WGS 在腫瘤學領域的應用預計將持續成長，從而推動市場擴張。

對資料隱私和安全的擔憂

基因組資料高度敏感，包含個體獨特的遺傳組成、疾病易感性及其他個人特徵等資訊。未授權存取基因組數據的風險引發了人們對這些敏感資訊被濫用的擔憂。如果基因組資料落入惡意第三方之手，則可能被用於各種用途，包括身分盜竊、保險歧視及其他惡意活動。若未能妥善解決這些問題，可能會阻礙全基因組定序市場的發展。

新冠疫情的感染疾病

新冠疫情對全基因體定序市場的影響整體中性。疫情凸顯了遺傳學在理解和預防感染疾病的重要作用。全球研究人員已利用全基因組定序技術研究SARS-CoV-2病毒的基因組成和演化史。這進一步提升了遺傳學在個人化醫療中的重要性。然而，由於供應鏈中斷和研究目標變化等因素，市場也經歷了一些暫時性衝擊。

在預測期內，精準醫療領域預計將成為規模最大的領域。

精準醫療領域預計將成為高盈利市場。精準醫療旨在根據每位患者的個別特徵最佳化治療方案和醫療決策。全基因組定序透過全面分析個體的整個基因組，在精準醫療中發揮核心作用。這有助於最佳化藥物選擇和劑量。此外，全基因組定序還能提供更具成本效益的治療方案、增強患者自主權並提供個人化護理計劃，加速該領域的成長。

在預測期內，研究中心板塊預計將呈現最高的複合年成長率。

由於眾多研究領域的進步，研究中心板塊在預測期內預計將呈現最高的複合年成長率。全基因組定序（WGS）在研究中心內具有許多應用和優勢，有助於加深對遺傳學、基因組學和各種生物過程的理解。它還為闡明疾病機制、識別潛在治療標靶和開發個人化治療方案提供關鍵資訊。

市佔率最大的地區：

由於研發投入的增加，亞太地區預計將在預測期內佔據最大的市場佔有率。亞太地區的生物技術和醫療保健產業正呈現顯著成長。各國政府正在推出資助計畫和支持措施，以促進基因組技術在研究和臨床應用中的普及。該地區人口的多樣性以及遺傳疾病盛行率的不斷上升，也是推動市場擴張的因素。

複合年成長率最高的地區：

由於政府投入的增加，預計北美在預測期內將呈現最高的複合年成長率。該地區擁有許多專注於基因組學和個人化醫療的領導者。北美消費者對了解自身祖源、特定健康狀況的易感性以及其他基因組資訊表現出濃厚的興趣。此外，全基因組定序技術的進步及其在癌症治療中的應用也正在推動該地區的發展趨勢。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場公司（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域分類
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對重點公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 產品分析
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章：全球全基因組定序市場：依產品分類

  • 消耗品
  • 裝置
  • 服務

第6章：全球全基因組定序市場：按類型分類

  • 小規模全基因測序
  • 大規模全基因測序

第7章：全球全基因體定序市場：依工作流程分類

  • 數據分析
  • 定序
  • 序列預處理

第8章：全球全基因組定序市場：依技術分類

  • 桑格定序
  • 微陣列
  • 聚合酵素鏈鎖反應
  • 次世代定序
  • 其他技術

第9章：全球全基因組定序市場：按應用領域分類

  • 藥物發現與開發
  • 診斷
  • 精準醫療
  • 其他用途

第10章：全球全基因組定序市場：依最終用戶分類

  • 學術機構
  • 醫院和診所
  • 研究機構
  • 製藥和生物技術公司
  • 其他最終用戶

第11章：全球全基因體定序市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第12章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第13章：公司簡介

  • Siemens Healthineers
  • Thermo Fisher Scientific Inc
  • F. Hoffmann-La Roche Ltd
  • Danaher Corporation
  • Agilent Technologies Inc
  • Illumina Inc
  • Complete Genomics
  • QIAGEN NV
  • GeneDx
  • Merck KGaA
  • Abbott
  • Eurofins Scientific
  • Oxford Nanopore Technologies
  • Bio-Rad Laboratories, Inc
  • Macrogens Inc
Product Code: SMRC24598

According to Stratistics MRC, the Global Whole Genome Sequencing Market is accounted for $66.0 billion in 2026 and is expected to reach $182.0 billion by 2034 growing at a CAGR of 13.5% during the forecast period. Whole Genome Sequencing (WGS) is a comprehensive method used to determine the complete DNA sequence of an organism's genome. The genome is the complete set of DNA, including all of the genes and non-coding regions that carry the genetic information for the development, functioning, and maintenance of an organism. Whole genome sequencing plays a critical role in advancing both research and clinical applications in the field of genomics.

According to the Centers for Disease Control and Prevention statistics, around 1 in every 707 newborn children in the U.S. suffer from Down syndrome, which accounts for approximately 5,568 children in the U.S.

Market Dynamics:

Driver:

Rising prevalence of genetic disorders

WGS is a powerful tool for identifying genetic variations associated with various disorders. As the prevalence of genetic disorders increases, there is a growing need for accurate and comprehensive diagnostic methods. WGS allows for a thorough examination of an individual's entire genome, providing insights into the genetic basis of diseases. It fuels the research efforts to better understand the underlying genetic mechanisms. Further, the rising awareness of the importance of early detection and intervention in managing genetic disorders contributes to the demand for WGS.

Restraint:

Limited clinical utility in certain conditions

In certain medical conditions, especially complex and multifactorial diseases, the genetic basis may not be well-defined or easily actionable. In some cases, the relevance of specific genomic findings to clinical outcomes may not be well-established. This lack of actionable information can limit the clinical utility of WGS, as healthcare providers may struggle to use the genetic data to inform treatment decisions. It also raises ethical concerns about how to handle such conditions. Thereby, it hinders the integration of WGS into clinical practice.

Opportunity:

Increasing adoption in oncology

Whole genome sequencing enables a comprehensive analysis of a patient's genetic makeup, allowing for a better understanding of the molecular drivers of cancer. It helps to identify specific genetic mutations and alterations that drive the growth of cancer cells. The use of WGS data in oncology research is instrumental in the identification of suitable candidates for clinical trials. As more clinical evidence is generated, and the technology becomes more accessible and cost-effective, the adoption of WGS in oncology is likely to continue its upward trajectory, driving market expansion.

Threat:

Data privacy & security concerns

Genomic data is highly sensitive and contains information about an individual's unique genetic makeup, predispositions to diseases, and potentially other personal traits. The risk of unauthorized access to genomic data raises concerns about the misuse of sensitive information. If genomic data falls into the wrong hands, it could be exploited for various purposes, including identity theft, insurance discrimination, or other malicious activities. Failure to adequately address these concerns can impede the growth of the whole genome sequencing market.

Covid-19 Impact

The covid pandemic had a neutral effect on the whole genome sequencing market. The pandemic highlighted the role that genetics plays in comprehending and preventing infectious illnesses. Whole genome sequencing has been used by researchers all around the world to examine the genetic composition and evolutionary history of the SARS-CoV-2 virus. This lightened the significance of genetics in personalized treatment. On the other hand, the market was momentarily impacted by variables including the interruption of supply networks and changes in research objectives.

The precision medicine segment is expected to be the largest during the forecast period

The precision medicine segment is estimated to have a lucrative. Precision medicine involves tailoring medical treatment and healthcare decisions to the individual characteristics of each patient. Whole genome sequencing plays a central role in precision medicine, providing a comprehensive analysis of an individual's entire genome. It helps to optimize drug selection and dosage. Additionally, it offers cost effective treatments, patient empowerment and personalized care plans which accelerates the segment growth.

The research centers segment is expected to have the highest CAGR during the forecast period

The research centers segment is anticipated to witness the highest CAGR growth during the forecast period, due to the advancements in a wide range of research fields. WGS offers a myriad of uses and benefits in research centers, contributing to the significant understanding of genetics, genomics, and various biological processes. It also provides critical information for understanding disease mechanisms, identifying potential therapeutic targets, and developing personalized treatment approaches.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the growing investment in R&D activities. The Asia-Pacific region has experienced substantial growth in the biotechnology and healthcare sectors. Governments have initiated funding programs and supportive policies to encourage the adoption of genomic technologies for research and clinical applications. The region's diverse population along with growing generic disorders is boosting the market's expansion.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to the rising government funding. The region hosts numerous leading biotechnology & pharmaceutical companies focused on genomics and personalized medicine. Consumers in North America have shown interest in learning about their ancestry, predisposition to certain health conditions, and other genomic information. Further, the rising innovation in whole genome sequencing and its application in cancer treatments are thereby augmenting the regional market trends.

Key players in the market

Some of the key players profiled in the Whole Genome Sequencing Market include Siemens Healthineers, Thermo Fisher Scientific Inc, F. Hoffmann-La Roche Ltd, Danaher Corporation, Agilent Technologies Inc, Illumina Inc, Complete Genomics, QIAGEN N.V., GeneDx, Merck KGaA, Abbott, Eurofins Scientific, Oxford Nanopore Technologies, Bio-Rad Laboratories, Inc and Macrogens Inc.

Key Developments:

In October 2023, Oxford Nanopore Technologies and Fabric Genomics collaborated to launch an integrated whole-genome sequencing solution to advance the future of paediatric patient care. The joint solution, which will be commercially available for deployment in CLIA/CAP labs, will support use of nanopore sequencing in neonatal/pediatric intensive care units.

In October 2023, Complete Genomics, a pioneering genomic sequencing company, launched its DNBSEQ-T20x2* product, which reduced the cost of whole genome sequencing to less than $100 per 30X WGS.

In August 2023, GeneDx and PacBio announced research collaboration with the University of Washington to study the capabilities of HiFi long-read whole genome sequencing (WGS) to increase diagnostic rates in pediatric patients with genetic conditions.

Products Covered:

  • Consumables
  • Instruments
  • Services

Types Covered:

  • Small Whole Genome Sequencing
  • Large Whole Genome Sequencing

Workflows Covered:

  • Data Analysis
  • Sequencing
  • Pre-Sequencing

Technologies Covered:

  • Sanger Sequencing
  • Microarray
  • Polymerase Chain Reaction
  • Next Generation Sequencing
  • Other Technologies

Applications Covered:

  • Drug Discovery & Development
  • Diagnostics
  • Precision Medicine
  • Other Applications

End Users Covered:

  • Academic Institutes
  • Hospitals & Clinics
  • Research Centers
  • Pharmaceutical & Biotechnology Companies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Whole Genome Sequencing Market, By Product

  • 5.1 Introduction
  • 5.2 Consumables
  • 5.3 Instruments
  • 5.4 Services

6 Global Whole Genome Sequencing Market, By Type

  • 6.1 Introduction
  • 6.2 Small Whole Genome Sequencing
  • 6.3 Large Whole Genome Sequencing

7 Global Whole Genome Sequencing Market, By Workflow

  • 7.1 Introduction
  • 7.2 Data Analysis
  • 7.3 Sequencing
  • 7.4 Pre-Sequencing

8 Global Whole Genome Sequencing Market, By Technology

  • 8.1 Introduction
  • 8.2 Sanger Sequencing
  • 8.3 Microarray
  • 8.4 Polymerase Chain Reaction
  • 8.5 Next Generation Sequencing
  • 8.6 Other Technologies

9 Global Whole Genome Sequencing Market, By Application

  • 9.1 Introduction
  • 9.2 Drug Discovery & Development
  • 9.3 Diagnostics
  • 9.4 Precision Medicine
  • 9.5 Other Applications

10 Global Whole Genome Sequencing Market, By End User

  • 10.1 Introduction
  • 10.2 Academic Institutes
  • 10.3 Hospitals & Clinics
  • 10.4 Research Centers
  • 10.5 Pharmaceutical & Biotechnology Companies
  • 10.6 Other End Users

11 Global Whole Genome Sequencing Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Siemens Healthineers
  • 13.2 Thermo Fisher Scientific Inc
  • 13.3 F. Hoffmann-La Roche Ltd
  • 13.4 Danaher Corporation
  • 13.5 Agilent Technologies Inc
  • 13.6 Illumina Inc
  • 13.7 Complete Genomics
  • 13.8 QIAGEN N.V.
  • 13.9 GeneDx
  • 13.10 Merck KGaA
  • 13.11 Abbott
  • 13.12 Eurofins Scientific
  • 13.13 Oxford Nanopore Technologies
  • 13.14 Bio-Rad Laboratories, Inc
  • 13.15 Macrogens Inc

List of Tables

  • Table 1 Global Whole Genome Sequencing Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Whole Genome Sequencing Market Outlook, By Product (2023-2034) ($MN)
  • Table 3 Global Whole Genome Sequencing Market Outlook, By Consumables (2023-2034) ($MN)
  • Table 4 Global Whole Genome Sequencing Market Outlook, By Instruments (2023-2034) ($MN)
  • Table 5 Global Whole Genome Sequencing Market Outlook, By Services (2023-2034) ($MN)
  • Table 6 Global Whole Genome Sequencing Market Outlook, By Type (2023-2034) ($MN)
  • Table 7 Global Whole Genome Sequencing Market Outlook, By Small Whole Genome Sequencing (2023-2034) ($MN)
  • Table 8 Global Whole Genome Sequencing Market Outlook, By Large Whole Genome Sequencing (2023-2034) ($MN)
  • Table 9 Global Whole Genome Sequencing Market Outlook, By Workflow (2023-2034) ($MN)
  • Table 10 Global Whole Genome Sequencing Market Outlook, By Data Analysis (2023-2034) ($MN)
  • Table 11 Global Whole Genome Sequencing Market Outlook, By Sequencing (2023-2034) ($MN)
  • Table 12 Global Whole Genome Sequencing Market Outlook, By Pre-Sequencing (2023-2034) ($MN)
  • Table 13 Global Whole Genome Sequencing Market Outlook, By Technology (2023-2034) ($MN)
  • Table 14 Global Whole Genome Sequencing Market Outlook, By Sanger Sequencing (2023-2034) ($MN)
  • Table 15 Global Whole Genome Sequencing Market Outlook, By Microarray (2023-2034) ($MN)
  • Table 16 Global Whole Genome Sequencing Market Outlook, By Polymerase Chain Reaction (2023-2034) ($MN)
  • Table 17 Global Whole Genome Sequencing Market Outlook, By Next Generation Sequencing (2023-2034) ($MN)
  • Table 18 Global Whole Genome Sequencing Market Outlook, By Other Technologies (2023-2034) ($MN)
  • Table 19 Global Whole Genome Sequencing Market Outlook, By Application (2023-2034) ($MN)
  • Table 20 Global Whole Genome Sequencing Market Outlook, By Drug Discovery & Development (2023-2034) ($MN)
  • Table 21 Global Whole Genome Sequencing Market Outlook, By Diagnostics (2023-2034) ($MN)
  • Table 22 Global Whole Genome Sequencing Market Outlook, By Precision Medicine (2023-2034) ($MN)
  • Table 23 Global Whole Genome Sequencing Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 24 Global Whole Genome Sequencing Market Outlook, By End User (2023-2034) ($MN)
  • Table 25 Global Whole Genome Sequencing Market Outlook, By Academic Institutes (2023-2034) ($MN)
  • Table 26 Global Whole Genome Sequencing Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
  • Table 27 Global Whole Genome Sequencing Market Outlook, By Research Centers (2023-2034) ($MN)
  • Table 28 Global Whole Genome Sequencing Market Outlook, By Pharmaceutical & Biotechnology Companies (2023-2034) ($MN)
  • Table 29 Global Whole Genome Sequencing Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.